Stay updated with breaking news from Iveric Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing eye-care market.
/PRNewswire/ -- DelveInsight's Stargardt Disease Market Insights report includes a comprehensive understanding of current treatment practices, Stargardt...
/PRNewswire/ -- DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment...
Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah’s joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations